Combinational dual drug delivery system to enhance the care and treatment of gastric cancer patients
Authors:
Open Access
- 1 January 2020
- journal article
- research article
- Published by Taylor & Francis in Drug Delivery
- Vol. 27 (1) , 1491-1500
Abstract
Gastric cancer is a frequently occurring cancer with high mortality each year worldwide. Finding new and effective therapeutic strategy against human gastric cancer is still urgently required. Hence, we have established a new method to achieve treatment-actuated modifications in a tumor microenvironment by utilizing synergistic activity between two potential anticancer drugs. Dual drug delivery of gemcitabine (GEM) and Camptothecin-11 (CPT-11) exhibits a great anti-cancer potential, as GEM enhances the effect of CPT-11 treatment of human gastric cells by providing microenvironment stability. However, encapsulation of GEM and CPT-11 obsessed by poly(lactic-co-glycolic acid) (PLGA)-based nanoparticles (NPs) is incompetent owing to unsuitability between the binary free GEM and CPT-11 moieties and the polymeric system. Now, we display that CPT-11 can be prepared by hydrophobic covering of the drug centers with dioleoylphosphatidic acid (DOPA). The DOPA-covered CPT-11 can be co-encapsulated in PLGA NPs alongside GEM to stimulate excellent anticancer property. The occurrence of the CPT-11 suggestively enhanced the encapsulations of GEM into PLGA NPs (GEM-CPT-11 NPs). Formation of the nanocomposite (GEM-CPT-11 NPs) was confirmed by FTIR and X-ray spectroscopic techniques. Further, the morphology of GEM NPs, CPT-11 NPs, and GEM-CPT-11 NPs and NP size was examined by transmission electron microscopy (TEM), respectively. Furthermore, GEM-CPT-11 NPs induced significant apoptosis in human gastric NCI-N87 and SGC-791 cancer cells in vitro. The morphological observation and apoptosis were confirmed by the various biochemical assays (AO-EB, nuclear staining, and annexin V-FITC). In addition, evaluation of the hemolysis assay with erythrocytes of human shows excellent biocompatibility of free GEM, free CPT-11, GEM NPs, CPT-11 NPs, and GEM-CPT-11 NPs. The results suggest that GEM-CPT-11 NPs are one of the promising nursing cares for human gastric cancer therapeutic candidates worthy of further investigations. Graphical AbstractKeywords
This publication has 63 references indexed in Scilit:
- New Methods for Improved Characterization of Silica Nanoparticle-Based Drug Delivery SystemsLangmuir, 2013
- Two-Wave Nanotherapy To Target the Stroma and Optimize Gemcitabine Delivery To a Human Pancreatic Cancer Model in MiceACS Nano, 2013
- Innovative pharmaceutical development based on unique properties of nanoscale delivery formulationNanoscale, 2013
- In Vivo Gastric Cancer Targeting and Imaging Using Novel Symmetric Cyanine Dye-Conjugated GX1 Peptide ProbesBioconjugate Chemistry, 2013
- Functional block copolymer assemblies responsive to tumor and intracellular microenvironments for site-specific drug delivery and enhanced imaging performanceChemical Society Reviews, 2013
- Discovery of SLC3A2 Cell Membrane Protein as a Potential Gastric Cancer Biomarker: Implications in Molecular ImagingJournal of Proteome Research, 2012
- Paclitaxel/Tetrandrine Coloaded Nanoparticles Effectively Promote the Apoptosis of Gastric Cancer Cells Based on “Oxidation Therapy”Molecular Pharmaceutics, 2011
- Nanomedicine for Cancer: Lipid-Based Nanostructures for Drug Delivery and MonitoringAccounts of Chemical Research, 2011
- Cathepsin S Mediates Gastric Cancer Cell Migration and Invasion via a Putative Network of Metastasis-Associated ProteinsJournal of Proteome Research, 2010
- Acridine Orange/Ethidium Bromide (AO/EB) Staining to Detect ApoptosisCold Spring Harbor Protocols, 2006